BioCatalystWatch
ONCWorkspace / ONC / OverviewCompany library
Price
Market cap
Next catalystDec 13, 2026BRUKINSA plus rituximab — MANGROVE · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

BTK

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

BTK

PreINDP1P2FilingApproved
Upcoming / outlook

BEQALZI (sonrotoclax)

BCL2

PreINDP1P2FilingApproved
Upcoming / outlook

BRUKINSA (zanubrutinib)BRUKINSA plus rituximab — MANGROVE

BTK

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

TEVIMBRA (tislelizumab)

PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

GPC3 × 4-1BB

PreINDP1P2FilingApproved
Upcoming / outlook

ZIIHERA (zanidatamab)

HER2

PreINDP1P2P3FilingApproved
Upcoming / outlook

GPC3 × 4-1BB

PreINDP1P2FilingApproved
Upcoming / outlook

GPC3 × 4-1BB

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

BRUKINSA (zanubrutinib)BRUKINSA plus rituximab — MANGROVE

BTK

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

GPC3 × 4-1BB

PreINDP1P2FilingApproved
Upcoming / outlook

GPC3 × 4-1BB

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

BGB-16673

BTK

PreINDP1P2P3FilingApproved
BEQALZI (sonrotoclax)

BCL2

PreINDP1P2P3FilingApproved
BG-75202

KAT6A × KAT6B

PreINDP1P2P3FilingApproved
BG-75202

KAT6A × KAT6B

PreINDP1P2P3FilingApproved

Partner / License out

STEAP1 × CD3

PreINDP1P2P3FilingApproved

Approved / commercial

TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved
TEVIMBRA (tislelizumab)

PD-1

Approved

PreINDP1P2P3FilingApproved

History / paused

TYK2

PreINDP1P2P3FilingApproved

LAG-3

PreINDP1P2P3FilingApproved

LAG-3

PreINDP1P2P3FilingApproved

LAG-3

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ONC PR & News

PR & News

ONC SEC archive